Citra Anticoagulants Announces CE Mark Approval for LOXXIT™ Catheter Lock Solution

Share Article

Citra Anticoagulants, Inc. a worldwide distributor of citrate-based anticoagulants received CE Mark approval for LOXXIT™ Catheter Lock Solution.

Citra Anticoagulants, Inc. a leading, developer and worldwide distributor of citrate-based anticoagulants reported today that it has received CE Mark approval for LOXXIT™ Catheter Lock Solution. This regulatory achievement clears the way for Citra to market and distribute this product throughout the European Union and in other countries that recognize the CE Mark.

LOXXIT™ Catheter Lock Solution, 46.7% Trisodium Citrate Dihydrate, 5 mL, is a sterile solution that prevents the coagulation of blood, eliminates the growth of microorganisms in any type of intravenous catheter, and prevents biofilm formation because it eliminates the growth of bacteria, yeast, and fungi in the catheter lumen. LOXXIT™ is a preventive-action product and was designed to prevent problems from occurring rather than treating problems that have occurred.

In September 2007, Citra signed an exclusive Marketing Services Agreement with H.A.C. Pharma which appoints H.A.C. Pharma as the sole representative to promote the marketing and sales activities of LOXXIT™ Catheter Lock Solution to distributors in Europe, the Middle East, and Africa.

For more information on LOXXIT™ Catheter Lock Solution, contact H.A.C. Pharma if you are located in Europe, the Middle East, or Africa, or contact Citra Anticoagulants, Inc. for the rest of the world.

About Citra Anticoagulants
Headquartered in Braintree, Massachusetts, 10 minutes outside of Boston, Massachusetts, Citra Anticoagulants, Inc. markets and distributes a multitude of citrate-based anticoagulants to the worldwide medical arena. For more information about Citra and our products, visit our website at

Team Citra embraces the mission to develop and market safe and effective citrate-based anticoagulants for the medical community, while providing outstanding customer service. Citra's products are used in many different applications: from the anticoagulant of choice in the preparation of platelet rich plasma, which is used as an aid in wound healing, to the anticoagulant of choice for the collection of granulocytes which are used to support patients undergoing cancer therapy, and to a superb catheter lock solution where the product functions as an anticoagulant and an antimicrobial agent.

About H.A.C. Pharma
H.A.C. Pharma is headquartered in Caen, France. It is a pharmaceutical marketing company focused on specialty therapeutic areas. The company commercializes drugs, medical devices, and food supplements for medical purposes in France and throughout the world. For more information and how to contact H.A.C. Pharma, visit


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ronald H. Lewis, President

Adrienne Summers
Visit website